Minghui Pharmaceutical (Hangzhou) Ltd clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 2 with minor changes only.

1. Notable

   Treatment of Active Thyroid Eye Disease With MHB018A in a…Treatment of Active Thyroid Eye Disease With MHB018A in a Randomized, Placebo-Controlled Study

   Recruitment opened

   Minghui Pharmaceutical (Hangzhou) Ltd·Phase 3· NCT07622108· Registry history of NCT07622108 on ClinicalTrials.gov (opens the registry)

   Updated Oct 14, 2026

2. Notable

   Treatment of Chronic Thyroid Eye Disease With MHB018A

   Recruitment opened

   Minghui Pharmaceutical (Hangzhou) Ltd·Phase 3· NCT07622121· Registry history of NCT07622121 on ClinicalTrials.gov (opens the registry)

   Updated Oct 14, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.